...
首页> 外文期刊>Bone marrow transplantation >Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors.
【24h】

Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors.

机译:前瞻性研究类固醇难治性或类固醇抵抗性广泛性慢性移植物抗宿主病的体外光透疗法:结合预后因素的反应和生存分析。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

We enrolled 25 patients with extensive, steroid-refractory chronic graft-versus-host disease (cGVHD) in a prospective trial evaluating the efficacy of extracorporeal photophoresis (ECP) in both skin and visceral cGVHD. The median time from transplant to initiation of ECP was 790 days. ECP was administered for 2 consecutive days every 2 weeks in 17 patients and once a week in eight patients until best response or stable disease. The median duration of therapy was 9 months (range 3-24 months). In all, 20 patients had improvement in cutaneous GVHD and six had healing of oral ulcerations. Steroid sparing or discontinuation of immunosuppressive medications was possible in 80% of patients. Response rates were similar between patients receiving treatment weekly vs every 2 weeks and in patients commencing ECP less than vs greater than 18 months from transplant (70 vs 66%). When patients were stratified based on the Akpek prognostic score, there was no difference in overall response between the favorable (Akpekscore<2.5) and unfavorable risk groups, but patients with progressive onset cGVHD tended to have a higher response than those with de novo onset. In summary, we report improvement in skin and/or visceral cGVHD in 71% overall and 61% of high-risk patients.
机译:我们在一项前瞻性试验中招募了25名患有广泛性,类固醇难治性慢性移植物抗宿主病的患者,以评估皮肤和内脏cGVHD体外荧光疗法(ECP)的疗效。从移植到开始ECP的中位时间为790天。在17例患者中,每2周连续2天给予ECP; 8例患者中,每周一次给予ECP,直至达到最佳反应或疾病稳定。中位治疗时间为9个月(范围3-24个月)。总共有20例患者皮肤GVHD改善,其中6例口腔溃疡愈合。 80%的患者有可能保留类固醇或停用免疫抑制药物。每周接受治疗的患者与每两周接受治疗的患者以及开始接受ECP的患者相比,移植后18个月以上与18个月以上的患者,缓解率相似(70%vs 66%)。当根据Akpek的预后评分对患者进行分层时,有利的(Akpekscore <2.5)组和不利的危险组之间的总体反应没有差异,但是进行性cGVHD发作的患者倾向于比从头发作的患者更高的应答。总之,我们报告总体上71%的高危患者和61%的高危患者的皮肤和/或内脏cGVHD改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号